Optimizing Post–CAR T Cell Monitoring: Evidence Across Lisocabtagene Maraleucel (liso-cel) Pivotal Clinical Trials and Real-World Experience

home / between-the-lines / optimizing-post-car-t-cell-monitoring-evidence-across-lisocabtagene-maraleucel-liso-cel-pivotal-clinical-trials-

Mazyar Shadman, MD, MPH, and Sayeef Mirza, MD, MPH, FACP, discuss how real-world data from over 1500 patients demonstrates that CAR T-cell therapy (CAR T) toxicities like cytokine release syndrome and neurotoxicity occur predominantly within the first 2 weeks post infusion, supporting the potential for reduced monitoring requirements and improved patient access to these lifesaving treatments.

2 experts in this video

EP. 1: The Expanding CAR T Landscape: FDA-Approved Therapies and Clinical Impact Across B-Cell Malignancies

Mazyar Shadman, MD, MPH;Sayeef Mirza, MD, MPH, FACP
June 23rd 2025

Panelists discuss how CAR T cell therapy has transformed lymphoma treatment with multiple FDA-approved products showing 70% to 80% overall response rates and 50% to 60% complete response rates across different B-cell malignancies, while emphasizing the importance of comparing clinical trial data with real-world evidence to understand true efficacy and safety profiles.

2 experts in this video

EP. 2: CAR T Monitoring Strategies: Balancing Patient Safety With Quality of Life Considerations

Mazyar Shadman, MD, MPH;Sayeef Mirza, MD, MPH, FACP
June 23rd 2025

Panelists discuss how CAR T monitoring requirements have evolved from initially conservative inpatient approaches to more flexible outpatient strategies, exploring ways to reduce the burden of mandatory 30-plus-day proximity requirements while maintaining patient safety and improving treatment accessibility.